Dynamic Changes in FOLR1 Expression During Platinum/Taxane and Mirvetuximab Soravtansine Therapy in Ovarian Cancer

IGCS 2026

Oct 01, 2026
Oncology
Presentation

Yan Zhang, Yuanqing Ye, Shuangxi Ji, Shelley Macneil, Shuyu Li, Michael Nagle, Pallavi Sachdev

Introduction
Folate receptor alpha (FRα), encoded by the FOLR1 gene, is a validated therapeutic target in ovarian cancer (OC). Understanding how standard chemotherapy/FRα-directed therapy modulate FOLR1-expression can inform patient selection/treatment sequencing/mechanisms of resistance.

 

Methods
We analyzed real-world RNAseq/clinical data from the Tempus Lens database across two OC cohorts. In cohort-1, patients received first-line platinum+taxane (without bevacizumab) and had paired pre-/on-treatment samples(n=20) or paired pre-/post-treatment samples(n=22). On-treatment samples were obtained ≥45 days before real-world progressive disease (rwPD); samples were considered post-treatment if collected <45 days before rwPD/after rwPD. Cohort-2 included patients treated with mirvetuximab soravtansine(MIRV) monotherapy with unpaired flanking pre-treatment samples(n=17) and flanking on- or post-treatment samples(n=11) without intervening therapy. Paired Wilcoxon signed-rank tests were applied for the chemotherapy cohort; analysis of covariance (adjusting for age/specimen site/sampling interval) was used for the MIRV cohort.

 

Results
MIRV therapy was associated with a significant decrease in FOLR1-expression(p=0.006) with a large effect size(Cohen’s d=−1.46). Following platinum+taxane chemotherapy, FOLR1-expression was decreased in 15/20(75%) on-treatment samples(p=0.036). In contrast, no significant difference was observed between pre-/post-treatment samples(p=0.75), indicating chemotherapy-associated suppression was not sustained after treatment completion or progression.

 

Conclusion/Implications
Platinum+taxane chemotherapy and MIRV both reduce FOLR1-expression. Reduction with chemotherapy appears transient, occurring only during treatment/not persisting post-therapy. This treatment-state–dependent modulation suggests that FRα-expression is dynamically regulated rather than durably lost under cytotoxic pressure, underscoring the importance of contemporaneous FRα-assessment when selecting patients for FRα-targeted therapies. Given the modest sample sizes and real-world heterogeneity, these findings should be considered preliminary and require validation in larger cohorts.